Skip to main
IRD

Opus Genetics (IRD) Stock Forecast & Price Target

Opus Genetics (IRD) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Opus Genetics is expected to see strong growth in the future due to their innovative gene therapy pipeline, potential for profitability through royalties and milestones, and expansion opportunities through rare retinal disease treatments and new methods of gene delivery. Their strong partnerships and funding also bode well for their future success.

Bears say

Opus Genetics is currently in a strong position with a portfolio of seven AAV-based programs targeting IRDs, and potential first-mover advantage. However, their reliance on the success of their two lead gene therapy programs, OPGx-LCA5 and OPGx-BEST1, also poses significant risk to their business. With a heavy focus on clinical development and limited commercialization experience, Opus may struggle to effectively market and commercialize their products if they are successfully approved. Additionally, there are other risks to consider such as potential competition, intellectual property challenges, and financial constraints. Overall, despite the potential for a large market opportunity, the risks associated with Opus Genetics make their stock outlook negative.

Opus Genetics (IRD) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Opus Genetics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Opus Genetics (IRD) Forecast

Analysts have given Opus Genetics (IRD) a Buy based on their latest research and market trends.

According to 10 analysts, Opus Genetics (IRD) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Opus Genetics (IRD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.